Knowthestock.com
AGIO - Agios Pharmaceuticals Inc

Sell

Weak GrowthEarnings/Profit is Negative

22%

based on last 5 year data.
Income Statement is WEAK
Revenue Growth is 465.16%
Operating Income is Negative but improving
Net Income is Negative but improving
Earnings Per Share (EPS) is Negative but improving
Net Margin is -161.11%
Balance Sheet is STRONG
Current Asset to Current Liability Ratio is 6.74
Debt Ratio is 0.53
Current Debt to Net Income Ratio not available
Total Debt to Total Assets Ratio is 0.0
Cash Flow is WEAK
Cash from Operations is Negative but improving
Capital Expenditure not available
Net Increase in Cash is Positive
Long Term Score Trend is NEUTRAL
Investment Risk is High
based on last 4 quarter data.
Unless specified, all values are in USD Millions. Data extracted from SEC Filing and are subject to processing and input errors.
Agios Pharmaceuticals Inc (AGIO) - http://www.agios.com/
Agios Pharmaceuticals Inc. is a public American pharmaceutical company focused on developing small-molecule anti-cancer therapeutics targeting cancer cell metabolism via the growth factor pathway. Among the proteins under investigation by the company are IDH1 and IDH2. The company was founded in 2008 by Lewis Cantley, Tak Mak and Craig Thompson. Agios is a Delaware corporation headquartered in Cambridge, Massachusetts. The company tendered an initial public offering in July 2013. In 2012, Agios was named among the defendants in a lawsuit against one of its founders, Craig Thompson, alleging that Thompson used research illegally taken from the Abramson Family Cancer Research Institute in research at Agios.
Exchange - NASDAQ/NMS (GLOBAL MARKET)
Industry - Pharmaceutical Preparation Manufacturing
Sector - Manufacturing
CEO - Jacqualyn Fouse
Employees - 536
    Close


Disclaimer - Investment in securities involves substantial risk and could result in significant loss. It is not suitable for every investor. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser. We may own some of the securities mentioned in this website.
Know the Stock © 2021 and future.